SARS-CoV-2 in Spent Dialysate from Chronic Peritoneal Dialysis Patients with COVID-19

Kidney360. 2020 Dec 1;2(1):86-89. doi: 10.34067/KID.0006102020. eCollection 2021 Jan 28.

Abstract

Background: To date, it is unclear whether SARS-CoV-2 is present in spent dialysate from patients with COVID-19 on peritoneal dialysis (PD). Our aim was to assess the presence or absence of SARS-CoV-2 in spent dialysate from patients on chronic PD who had a confirmed diagnosis of COVID-19.

Methods: Spent PD dialysate samples from patients on PD who were positive for COVID-19 were collected between March and August 2020. The multiplexed, real-time RT-PCR assay contained primer/probe sets specific to different SARS-CoV-2 genomic regions and to bacteriophage MS2 as an internal process control for nucleic acid extraction. Demographic and clinical data were obtained from patients' electronic health records.

Results: A total of 26 spent PD dialysate samples were collected from 11 patients from ten dialysis centers. Spent PD dialysate samples were collected, on average, 25±13 days (median, 20; range, 10-45) after the onset of symptoms. The temporal distance of PD effluent collection relative to the closest positive nasal-swab RT-PCR result was 15±11 days (median, 14; range, 1-41). All 26 PD effluent samples tested negative at three SARS-CoV-2 genomic regions.

Conclusions: Our findings indicate the absence of SARS-CoV-2 in spent PD dialysate collected at ≥10 days after the onset of COVID-19 symptoms. We cannot rule out the presence of SARS-CoV-2 in spent PD dialysate in the early stage of COVID-19.

Keywords: COVID-19; RT-PCR; SARS-CoV-2; chronic kidney disease; dialysis; dialysis solutions; peritoneal dialysis.

MeSH terms

  • COVID-19*
  • Dialysis Solutions
  • Humans
  • Peritoneal Dialysis* / adverse effects
  • SARS-CoV-2 / genetics

Substances

  • Dialysis Solutions